Study Summary
This trial is testing two new drugs, CC-220 and CC-99282, to see if they are effective in treating a-BCL (a type of cancer). The trial has two parts: first, a dose escalation to find the best dose of the new drugs to use, and second, a randomized expansion to test the new drugs at the recommended dose.
- B-Cell Lymphoma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
5 Primary · 27 Secondary · Reporting Duration: Up to 4 years
Trial Safety
Safety Progress
Trial Design
4 Treatment Groups
Administration of CC-220 with R-CHOP-21
1 of 4
Administration of CC-99282 with polatuzumab-R-CHP
1 of 4
Administration of CC-220 with polatuzumab-R-CHP
1 of 4
Administration of CC-99282 with R-CHOP-21
1 of 4
Experimental Treatment
174 Total Participants · 4 Treatment Groups
Primary Treatment: Rituximab · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are there various facilities in the United States that are facilitating this clinical study?
"This medical trial has been approved to operate out of the Mayo Clinic Jacksonville - PPDS in Jacksonville, Florida, Mayo Clinic Rochester in Minnesota and Vanderbilt University Medical Center in Tennessee. Additionally, there are 10 more sites across America authorized for recruitment." - Anonymous Online Contributor
Are there any recruitment opportunities for this medical experiment?
"Clinicaltrials.gov provides evidence that this clinical trial is still in search of participants, having been initially published on September 15th 2021 and last updated October 11th 2022." - Anonymous Online Contributor
Is there a documented history of research with Rituximab?
"Since 1993, there have been 2583 studies conducted on the efficacy of rituximab from National Institutes of Health Clinical Center in Rockville Pike. Presently, 1478 trials are still ongoing with many based out of Jacksonville, Florida." - Anonymous Online Contributor
What goals is the trial attempting to attain?
"According to Celgene, the primary objective of this clinical trial will be measured in a 21-day time period and is focused on safety and tolerance for CC-220 and CC-99282. Aside from the main aim, researchers are assessing other pharmacokinetic parameters such as Area under the plasma concentration-time curve (AUC), Time to maximum plasma concentration (Tmax) and Apparent volume of distribution (V/F)." - Anonymous Online Contributor
What impact does Rituximab have on a person's overall health?
"As it is a Phase 1 clinical trial, our team at Power rates Rituximab's safety as low (1), due to limited evidence of its effectiveness and safety." - Anonymous Online Contributor
What is the current enrollment size for this investigation?
"Celgene, the sponsor of this trial, needs 116 qualified participants to proceed. The study will be conducted in both Mayo Clinic Jacksonville - PPDS situated in Jacksonville, Florida and Mayo Clinic Rochester located in Minnesota's largest city." - Anonymous Online Contributor
How is Rituximab usually deployed to treat patients?
"Rituximab is widely used to treat ulcerative colitis and has also been shown to be effective in the management of conditions like acute retinal necrosis due to varicella-zoster virus, multiple myeloma, and tuberculous meningitis." - Anonymous Online Contributor